Trial reportBone marrow transplantation2012
Comparison of early quality of life outcomes in autologous and allogeneic transplant patients.
Trial report in Bone marrow transplantation, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed.
- Patient-Reported Outcome Results From the Open-Label, Randomized Phase III Myeloma X Trial Evaluating Salvage Autologous Stem-Cell Transplantation in Relapsed Multiple Myeloma.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2019Trial
- Patient-Reported Oral Symptoms and Their Impact on Well-Being After Haematopoietic Cell Transplantation.Oral diseases · 2026Observational
- Quality of life and symptom burden in hematological cancer patients receiving hematopoietic stem cell transplantation: an observational study at Regional Cancer Centre, India.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2024Observational
- Exercise in allogeneic bone marrow transplantation: a qualitative representation of the patient perspective.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2022Article
- Psychosocial aspects of hematopoietic stem cell transplantation.World journal of transplantation · 2021Review
- Functional capacity, pulmonary function, and quality of life in hematopoietic stem cell transplantation survivors.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2021Article
- Hematopoietic stem cell transplantation and quality of life during the first year of treatment.Revista latino-americana de enfermagem · 2018Observational
- Everyday life following hematopoietic stem cell transplantation: decline in physical symptoms within the first month and change-related predictors.Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation · 2018Article
- Allogeneic stem-cell transplantation for multiple myeloma: a systematic review and meta-analysis from 2007 to 2017.Cancer cell international · 2018Article
- Myeloma in Elderly Patients: When Less Is More and More Is More.American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting · 2017Review
- Patient education in allogeneic hematopoietic cell transplant: what patients wish they had known about quality of life.Bone marrow transplantation · 2014Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The Functional Assessment of Cancer Therapy-Bone Marrow Transplant measures quality of life (QOL) in SCT patients. Prior reports found mixed results regarding QOL differences among autologous and allogeneic SCT patients. In addition, there is a paucity of literature examining differences in QOL patterns over time between autologous and allogeneic patients. The present study examines differences in QOL between patients free of clinical depression undergoing autologous (n = 41) and allogeneic (n = 64) SCT during early stages of treatment. Despite clinical differences, autologous and allogeneic patients demonstrated similar changes in QOL. The exception was the Functional subscale which indicated worse QOL for allogeneic patients at discharge (F test = 4.61, df = 1, P < 0.05); allogeneic patients (Mean = 13.06, s.d. = 5.36) indicated they were less able to function at work and were less accepting of their illness than autologous patients (Mean = 16.02, s.d. = 6.73). There was a significant main effect for time on nearly all QOL subscales (P < 0.05) demonstrating decline during treatment and return to baseline by discharge; only the Social Well-Being scale did not significantly change over time. These results help to understand patients' response to SCT in the earliest stages and ultimately help identify patients at risk who could benefit from therapeutic interventions.
Indexed as
Identifiers
22562082What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.